TORONTO, 20 March 2017 – Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”) an emerging medical device company focused on prostate care, today announced that it has successfully completed the first sale of a TULSA-PRO system in Finland to the Turku University Hospital (“Tyks”). The deal was completed in collaboration with Royal Philips (“Philips”), who is working in partnership with Profound to commercialize the TULSA-PRO system in Europe.
As the first TULSA-PRO sale in Finland, the agreement with Tyks continues Profound’s recent commercial progress into the European market, where the Company has sold systems in Spain, United Kingdom and Germany since receiving CE Mark designation in April 2016. It also represents yet another European sale through the Company’s collaboration with Philips.
Operation of the TULSA-PRO system will be administered under Dr. Roberto Blanco Sequeiros, Chairman of the Medical Imaging Center at Turku University Hospital and under a leading European urologist, Dr. Peter Boström. According to Dr. Blanco Sequeiros, the technology holds promise in multiple areas of prostate treatment and care, including focal therapy for localized prostate cancer, treatment of benign prostate hyperplasia, salvage radiation therapy and the debulking of tumours.
Ad Statistics
Times Displayed: 174422
Times Visited: 3180 For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
“While there have been significant medical advances in prostate care in recent years, there is no question that an unmet medical need and uncharted medical terrain remains,” commented Dr. Blanco Sequeiros. “Survival rates for prostate cancer are high, but current therapies often come with side effects that include erectile dysfunction, incontinence and bowel problems. Though further testing is required, the evidence is compelling, and suggests that the TULSA-PRO system could represent a major breakthrough in prostate treatment, offering patients a therapy that is safe, accurate and effective with minimal side effects. We are keen to assess its potential in both localized prostate cancer and other prostate conditions.”
“We are delighted that the Turku University Hospital has adopted the TULSA-PRO system, offering patients in Finland a minimally invasive alternative to existing prostate care therapies,” commented Arun Menawat, Profound’s CEO. “As Profound continues its expansion into Europe and other international markets, we look forward to the day when this procedure becomes the new standard of care, helping patients quickly return to their daily lives.”
